Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2014

01.05.2014 | Endocrine Tumors

Anaplastic Thyroid Carcinoma: A 25-year Single-Institution Experience

verfasst von: A. Mohebati, MD, M. DiLorenzo, BA, F. Palmer, BA, S. G. Patel, MD, D. Pfister, MD, N. Lee, MD, R. M. Tuttle, MD, A. R. Shaha, MD, J. P. Shah, MD, I. Ganly, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Anaplastic thyroid carcinoma (ATC) is among the most aggressive solid tumors accounting for 1–5 % of primary thyroid malignancies. In this retrospective review, we aim to evaluate the prognostic factors, treatment approaches, and outcomes of patients with ATC treated at a single institution.

Materials and Methods

We retrospectively identified 95 patients with ATC from an institutional database between 1985 and 2010. A total of 83 patients with sufficient records were included in this study. Patient, tumor, and treatment characteristics were recorded. Disease-specific survival (DSS) was determined by the Kaplan–Meier method, and factors predictive of outcome were determined by univariate and multivariate analysis.

Results

Of the 83 patients, 41 were male and 42 were female. The median age at presentation was 60 years (range 28–89 years) with a median survival of 8 months. The 1- and 2-year DSS were 33 and 23 %, respectively. On univariate analysis, age less than 60 years, clinically N0 neck, absence of clinical extrathyroidal extension (cETE), gross total resection, and multimodality treatment were statistically significant predictors of improved survival. On multivariate analysis, absence of cETE, multimodality therapy, and gross total resection were predictors of improved outcome.

Conclusions

In patients with locoregional limited disease, multimodality treatment with gross total surgical resection and postoperative radiotherapy with or without chemotherapy offers the best local control and DSS.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol. 1999;16:64–9.PubMedCrossRef Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol. 1999;16:64–9.PubMedCrossRef
3.
Zurück zum Zitat Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer. 1998;83:2638–48.PubMedCrossRef Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer. 1998;83:2638–48.PubMedCrossRef
4.
5.
Zurück zum Zitat Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid. 1998;8:715–26.PubMedCrossRef Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid. 1998;8:715–26.PubMedCrossRef
6.
Zurück zum Zitat Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13:453–64.PubMedCrossRef Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13:453–64.PubMedCrossRef
7.
Zurück zum Zitat Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103:1330–5.PubMedCrossRef Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103:1330–5.PubMedCrossRef
8.
Zurück zum Zitat Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer. 2000;89:202–17.PubMedCrossRef Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer. 2000;89:202–17.PubMedCrossRef
9.
Zurück zum Zitat Bakiri F, Djemli FK, Mokrane LA, Djidel FK. The relative roles of endemic goiter and socioeconomic development status in the prognosis of thyroid carcinoma. Cancer. 1998;82:1146–53.PubMedCrossRef Bakiri F, Djemli FK, Mokrane LA, Djidel FK. The relative roles of endemic goiter and socioeconomic development status in the prognosis of thyroid carcinoma. Cancer. 1998;82:1146–53.PubMedCrossRef
10.
Zurück zum Zitat Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001;91:2335–42.PubMedCrossRef Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001;91:2335–42.PubMedCrossRef
11.
Zurück zum Zitat McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001;130:1028–34.PubMedCrossRef McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001;130:1028–34.PubMedCrossRef
12.
Zurück zum Zitat Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990;66:321–30.PubMedCrossRef Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990;66:321–30.PubMedCrossRef
13.
Zurück zum Zitat Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:525–38, xi.PubMedCrossRef Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:525–38, xi.PubMedCrossRef
14.
Zurück zum Zitat Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid. 2011;21:1183–9.PubMedCrossRef Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid. 2011;21:1183–9.PubMedCrossRef
15.
Zurück zum Zitat Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg. 2012;36:1247–54.PubMedCrossRef Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg. 2012;36:1247–54.PubMedCrossRef
16.
Zurück zum Zitat Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg. 2001;25:617–22.PubMedCrossRef Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg. 2001;25:617–22.PubMedCrossRef
17.
Zurück zum Zitat Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC, Multimodality treatment for anaplastic thyroid carcinoma–treatment outcome in 75 patients. Radiother Oncol. 2009;92:100–4.PubMedCrossRef Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC, Multimodality treatment for anaplastic thyroid carcinoma–treatment outcome in 75 patients. Radiother Oncol. 2009;92:100–4.PubMedCrossRef
18.
Zurück zum Zitat Passler C, Scheuba C, Prager G, Kaserer K, Flores JA, Vierhapper H, et al. Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg. 1999;384:284–93.PubMedCrossRef Passler C, Scheuba C, Prager G, Kaserer K, Flores JA, Vierhapper H, et al. Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg. 1999;384:284–93.PubMedCrossRef
19.
Zurück zum Zitat Kihara M, Miyauchi A, Yamauchi A, Yokomise H. Prognostic factors of anaplastic thyroid carcinoma. Surg Today. 2004;34:394–8.PubMedCrossRef Kihara M, Miyauchi A, Yamauchi A, Yokomise H. Prognostic factors of anaplastic thyroid carcinoma. Surg Today. 2004;34:394–8.PubMedCrossRef
20.
Zurück zum Zitat Ito Y, Higashiyama T, Hirokawa M, Fukushima M, Inoue H, Yabuta T, et al. Investigation of the validity of UICC stage grouping of anaplastic carcinoma of the thyroid. Asian J Surg. 2009;32:47–50.PubMedCrossRef Ito Y, Higashiyama T, Hirokawa M, Fukushima M, Inoue H, Yabuta T, et al. Investigation of the validity of UICC stage grouping of anaplastic carcinoma of the thyroid. Asian J Surg. 2009;32:47–50.PubMedCrossRef
21.
Zurück zum Zitat Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol. 2002;9:57–64.PubMedCrossRef Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol. 2002;9:57–64.PubMedCrossRef
22.
Zurück zum Zitat Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86:1848–53.PubMedCentralPubMedCrossRef Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86:1848–53.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60:1137–43.PubMedCrossRef De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60:1137–43.PubMedCrossRef
24.
Zurück zum Zitat Dandekar P, Harmer C, Barbachano Y, Rhys-Evans P, Harrington K, Nutting C, et al. Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys. 2009;74:518–21.PubMedCrossRef Dandekar P, Harmer C, Barbachano Y, Rhys-Evans P, Harrington K, Nutting C, et al. Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys. 2009;74:518–21.PubMedCrossRef
25.
Zurück zum Zitat Wong CS, Van Dyk J, Simpson WJ. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol. 1991;20:3–9.PubMedCrossRef Wong CS, Van Dyk J, Simpson WJ. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol. 1991;20:3–9.PubMedCrossRef
26.
Zurück zum Zitat Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, et al. Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy. Head Neck. 2010;32:829–36.PubMed Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, et al. Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy. Head Neck. 2010;32:829–36.PubMed
27.
Zurück zum Zitat Jeong H, Kim YR, Kim KN, Choe JG, Chung JK, Kim MK. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006;33:875–82.PubMedCrossRef Jeong H, Kim YR, Kim KN, Choe JG, Chung JK, Kim MK. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006;33:875–82.PubMedCrossRef
28.
Zurück zum Zitat Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer. 1994;74:1348–54.PubMedCrossRef Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer. 1994;74:1348–54.PubMedCrossRef
29.
Zurück zum Zitat Junor EJ, Paul J, Reed JS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol. 1992;18:83–8.PubMed Junor EJ, Paul J, Reed JS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol. 1992;18:83–8.PubMed
30.
Zurück zum Zitat Kobayashi T, Asakawa H, Umeshita K, Takeda T, Maruyama H, Matsuzuka F, et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck. 1996;18:36–41.PubMedCrossRef Kobayashi T, Asakawa H, Umeshita K, Takeda T, Maruyama H, Matsuzuka F, et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck. 1996;18:36–41.PubMedCrossRef
31.
Zurück zum Zitat Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H, et al. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg. 1998;22:725–30.PubMedCrossRef Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H, et al. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg. 1998;22:725–30.PubMedCrossRef
32.
Zurück zum Zitat Lim SM, Shin SJ, Chung WY, Park CS, Nam KH, Kang SW, et al. Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J. 2012;53:352–7.PubMedCentralPubMedCrossRef Lim SM, Shin SJ, Chung WY, Park CS, Nam KH, Kang SW, et al. Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J. 2012;53:352–7.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Ito K, Hanamura T, Murayama K, Okada T, Watanabe T, Harada M, et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck. 2012;34:230–7.PubMedCrossRef Ito K, Hanamura T, Murayama K, Okada T, Watanabe T, Harada M, et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck. 2012;34:230–7.PubMedCrossRef
34.
Zurück zum Zitat Jereb B, Stjernsward J, Lowhagen T. Anaplastic giant-cell carcinoma of the thyroid. A study of treatment and prognosis. Cancer. 1975;35:1293–5.PubMedCrossRef Jereb B, Stjernsward J, Lowhagen T. Anaplastic giant-cell carcinoma of the thyroid. A study of treatment and prognosis. Cancer. 1975;35:1293–5.PubMedCrossRef
35.
Zurück zum Zitat Segerhammar I, Larsson C, Nilsson IL, Bäckdahl M, Höög A, Wallin G, et al. Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution. J Surg Oncol. 2012;106:981–6.PubMedCrossRef Segerhammar I, Larsson C, Nilsson IL, Bäckdahl M, Höög A, Wallin G, et al. Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution. J Surg Oncol. 2012;106:981–6.PubMedCrossRef
36.
Zurück zum Zitat O’Neill JP, Power D, Condron C, Bouchier-Hayes D, Walsh M. Anaplastic thyroid cancer, tumorigenesis and therapy. Ir J Med Sci. 2010;179:9–15.PubMedCrossRef O’Neill JP, Power D, Condron C, Bouchier-Hayes D, Walsh M. Anaplastic thyroid cancer, tumorigenesis and therapy. Ir J Med Sci. 2010;179:9–15.PubMedCrossRef
37.
Zurück zum Zitat Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16:17–44.PubMedCentralPubMedCrossRef Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16:17–44.PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Kojic SL, Strugnell SS, Wiseman SM. Anaplastic thyroid cancer: a comprehensive review of novel therapy. Expert Rev Anticancer Ther. 2011;11:387–402.PubMedCrossRef Kojic SL, Strugnell SS, Wiseman SM. Anaplastic thyroid cancer: a comprehensive review of novel therapy. Expert Rev Anticancer Ther. 2011;11:387–402.PubMedCrossRef
Metadaten
Titel
Anaplastic Thyroid Carcinoma: A 25-year Single-Institution Experience
verfasst von
A. Mohebati, MD
M. DiLorenzo, BA
F. Palmer, BA
S. G. Patel, MD
D. Pfister, MD
N. Lee, MD
R. M. Tuttle, MD
A. R. Shaha, MD
J. P. Shah, MD
I. Ganly, MD, PhD
Publikationsdatum
01.05.2014
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2014
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3545-5

Weitere Artikel der Ausgabe 5/2014

Annals of Surgical Oncology 5/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.